Monitor for rapid share price decline as the conversion mechanism creates downward pressure; watch for registration statement filing which will enable resale of conversion shares; assess whether this financing indicates cash flow distress given the high-cost terms
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 11 $0.0350entry
- T+1 · 8mo ago 0.00%α +1.48% · $0.0350
- T+5 · 8mo ago −5.71%α −3.53% · $0.0330
- T+20 · 7mo ago −2.86%α −3.38% · $0.0340
- T+60 · 6mo ago −65.71%α −77.24% · $0.0120
Price Chart
How similar events traded
Executive Summary
CERO Therapeutics raised $750,000 through a convertible promissory note with a principal of $937,500, bearing 10% interest and maturing August 6, 2027. The note is convertible into common stock at a discount (80% of the 5 lowest intraday prices over 20 days) or $0.05, whichever is lower, creating immediate dilution risk and increasing leverage.
Key Financial Metrics
Key Facts
- Raised $750,000 in exchange for a convertible note with $937,500 principal (25% premium)
- Note bears 10% annual interest and matures in August 2027
- Conversion price is the lesser of $0.05 or 80% of the 5 lowest intraday prices over 20 days prior to conversion
- Company must file registration statement for resale of conversion shares
- Unregistered private placement to accredited investor under Rule 506(b)
Financial Impact
$750,000 in new debt with significant dilution risk due to discount conversion and 25% premium
Risk Factors
- Significant dilution from discount-based conversion formula
- High interest rate (10%) increases financial burden
- Potential for death spiral financing if share price declines
- Registration requirement may flood market with new shares
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-025817 |
| Document: 0001213900-26-025817-index-headers.html | 0001213900-26-025817 |
| Document: 0001213900-26-025817-index.html | 0001213900-26-025817 |
| Document: 0001213900-26-025817.txt | 0001213900-26-025817 |
Track record
5 reports on CERO
3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +40.00% at T+60 after the Jul 13, 2026 report. 3 of 4 went positive at some point.
Filters
- Oct 7, 20265w ago 8-K Bearish 6/10 Entry $0.0951 Now $0.005000 +94.74% No price data
- Aug 31, 202611w ago 8-K Bearish 7/10 Entry $0.0120 to $0.0105 Now $0.005000 +58.33% ▲ +12.50% +13.68% vs SPY
- Jul 13, 202618w ago 25-NSE Bearish 7/10 Entry $0.0150 to $0.0100 Now $0.005000 +66.67% ▲ +33.33% +36.52% vs SPY
- Jun 26, 202620w ago 8-K Bearish 6/10 Entry $0.0110 to $0.009700 Now $0.005000 +54.55% ▲ +11.82% +11.56% vs SPY
- Mar 11, 202635w ago 8-K Bearish 7/10 Viewing Entry $0.0350 to $0.0340 Now $0.005000 +85.71% ▲ +2.86% +3.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers